Clinical trial · Interventional
TACE Combined With RFA/MV Treatment in Hepatocellular Carcinoma Beyond Milan Criterial
Clinical Trial of Transcatheter Arterial Chemoembolization Combined With Radiofrequency/Microwave Ablation in Hepatocellular Carcinoma Beyond Milan Criterial
NCT03636620CI-TRIAL-00034411TACE+RFAcompletedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study was designed to evaluate the effectiveness of radiofrequency /microwave ablation in patients with hepatocellular carcinoma beyond Milan Criteria.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| radiofrequency ablation/microwave ablation | Device | — | UNRESOLVED |
| Transcatheter arterial chemoembolization | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- TACE group
- description
- Transcatheter arterial chemoembolization
- interventionNames
- Device: Transcatheter arterial chemoembolization
- type
- EXPERIMENTAL
- label
- TACE+RFA/MV group
- description
- Transcatheter arterial chemoembolization and radiofrequency /microwave ablation
- interventionNames
- Device: Transcatheter arterial chemoembolization
- Device: radiofrequency ablation/microwave ablation
Primary outcomes (1)
- measure
- overall survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * patients diganosed with hepatocellualr carcinoma beyond Milan criteria * the presence of a single HCC tumor ≤7 cm in diameter, or multi-nodular HCC tumors (n ≤ 5) small than 7 cm in diameter; * Child-Pugh A or B * ECOG score 0-1; * prothrombin time ≤16 s; * white cell count ≥3,000/mm3, platelet count ≥40 x 109/L;Hb≥8.5 g/d; ALT/AST≤5×ULN;TB≤3mg/dl;alb≥2.8 g/dl ;Scr ≤2mg/dl Exclusion Criteria: * expected survival time \< 12 months before random assignment; * received anticancer surgery or procedure within one month before assignment; * concomitant use of any other anticancer therapy(except immunotherapy and herbal medicine ) ; * existence of portal of hepatic vein invation or extrahepatic metastases;existence of active infection ; * upper gastrointestinal hemorrhage within one month ; .other serious illness or medical condition.
References
Publications (0)
Data not yet available
No reference posted for this study.